CN101322726B - Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis - Google Patents
Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis Download PDFInfo
- Publication number
- CN101322726B CN101322726B CN2007101111410A CN200710111141A CN101322726B CN 101322726 B CN101322726 B CN 101322726B CN 2007101111410 A CN2007101111410 A CN 2007101111410A CN 200710111141 A CN200710111141 A CN 200710111141A CN 101322726 B CN101322726 B CN 101322726B
- Authority
- CN
- China
- Prior art keywords
- preparation
- total flavonoids
- herba clinopodii
- clinopodii polycephali
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 208000006454 hepatitis Diseases 0.000 title abstract description 10
- 231100000283 hepatitis Toxicity 0.000 title abstract description 7
- 229930003944 flavone Natural products 0.000 title description 4
- 235000011949 flavones Nutrition 0.000 title description 4
- 150000002213 flavones Chemical class 0.000 title 1
- 229930003935 flavonoid Natural products 0.000 claims abstract description 53
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 53
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 53
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 abstract description 13
- 238000002347 injection Methods 0.000 abstract description 11
- 239000007924 injection Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000006071 cream Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000007787 solid Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000034994 death Effects 0.000 abstract description 2
- 208000005252 hepatitis A Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 241001469911 Equisetum ramosissimum Species 0.000 abstract 5
- 239000002398 materia medica Substances 0.000 abstract 3
- 208000037319 Hepatitis infectious Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229940090044 injection Drugs 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 101710142246 External core antigen Proteins 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- VKOUCJUTMGHNOR-UHFFFAOYSA-N Diphenolic acid Chemical compound C=1C=C(O)C=CC=1C(CCC(O)=O)(C)C1=CC=C(O)C=C1 VKOUCJUTMGHNOR-UHFFFAOYSA-N 0.000 description 1
- 241000195952 Equisetaceae Species 0.000 description 1
- 241000616594 Equisetum ramosissimum subsp. debile Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese materia medica preparation with total flavonoids of equisetum ramosissimum desfontaines, a preparation method thereof, and the application thereof in preparation of medicines for treating hepatic diseases. The Chinese materia medica preparation with the total flavonoids of equisetum ramosissimum desfontaines of the invention consists of 0.3-85% of the extract of the active ingredient of equisetum ramosissimum desfontaines and 15-99.7% of a preparation which consists of pharmaceutical adjuvants and has various pharmaceutically acceptable dosage forms such as injection, oral solid preparation, cream and oral liquid, wherein, the content of the main active ingredient namely the total flavonoids of equisetum ramosissimum desfontaines in the extract of the active ingredient of the equisetum ramosissimum desfontaines is not less than 50%. The invention also discloses a preparation method of the Chinese materia medica preparation. The preparation of the invention has obvious antiviral function, good and unique effect on acute and chronic infectious hepatitis, and is safe and free from toxicity, provides a novel medicine with remarkable curative effect and convenient use for patients with hepatitis. The preparation has the advantages of promoting the recovery of the patients with hepatitis, lowering the death rate of the hepatitis, and reducing the onset of the liver cancer.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, specifically, relate to a kind of application that contains Chinese medicine preparation, preparation method and the said preparation of Herba Clinopodii Polycephali total flavonoids as the treatment liver disease drug.
Background technology
Various types of all over the world at present hepatopathy sickness rate are higher, and are especially higher at developing country's sickness rate.Though there are not reports such as nationwide epidemic diseases at home, show that from some areas investigation sickness rate surpasses 5%, the popular sternness that viral liver disease also is described of the Shanghai area extensive hepatitis A eighties.Someone estimates that the medicine for the treatment of at present hepatopathy in the world has 500 kinds more than, but does not in fact still have a kind of can really more controlling so far.Many hepatopaths are owing to can not get effective Drug therapy, and to nodular cirrhosis, the chronic active hepatitis that has continues not heal for a long time by development of chronic hepatitis, and some liver cirrhosis CALD further worsens into hepatocarcinoma.Pathological anatomy teaching and research room of last medical university is from the observation of 220 routine hepatocarcinoma postmortems and the analysis showed that the hepatitis of liver cancer patient and liver cirrhosis all occurs in before the hepatocarcinoma, and the importance of acute and chronic hepatitis treatment is described.
Because spread path and approach that viral hepatitis is propagated are a lot, it can make the people infect diseases such as chronic viral hepatitis or hepatic necrosis by dust, contact, food or blood product, still there is not the definite effective medicine and treat viral liver disease at present, therefore, to truly have the liver disease drug of curative effect be the task of top priority in research.
Herba Clinopodii Polycephali has another name called Radix Scorzonerae Albicaulis, Herba Eguiseti Debilis, and Herba equiseti ramosissimi, Herba Psychotriae Siamicaes etc. are the dry aerial parts of Equisetaceae plant Herba Clinopodii Polycephali Equisetumdebile Roxb..The function of successive dynasties book on Chinese herbal medicine record cures mainly and is expelling wind and clearing away heat, and the dehumidifying diuresis is used for conjunctival congestion and swelling pain, pterygium, and stranguria with turbid discharge, epistaxis is had blood in stool, hematuria, diseases such as toothache.The rarely seen report of application aspect hepatopathy.
The present invention carries out pharmacological screening to Herba Clinopodii Polycephali on the basis of folk remedy, think that Herba Clinopodii Polycephali has hepatitis virus resisting, effect such as protects the liver, and be better than present commercially available leading products lamivudine.
Summary of the invention
Problem to be solved by this invention is on the basis of existing pharmacological evaluation, and by extracting the active ingredient in the Herba Clinopodii Polycephali, preparation quality is stable, the Chinese medicine preparation of determined curative effect, the convenient treatment hepatopathy of using.
The Chinese medicine preparation of treatment hepatopathy disclosed by the invention is the preparation of the medically acceptable various dosage forms formed of 0.3-85% Herba Clinopodii Polycephali active component extract and 15-99.7% pharmaceutic adjuvant, wherein main active Herba Clinopodii Polycephali total flavonoids content 〉=50% in the Herba Clinopodii Polycephali active component extract by percentage by weight.
Medically acceptable various dosage forms of the present invention are injection (comprising liquid drugs injection, powder pin, lyophilizing pin, infusion solutions etc.), oral solid formulation (comprising all kinds of tablets, hard capsule, soft capsule, granule, powder etc.), cream and oral liquid.
Another technical problem to be solved by this invention provides the preparation method of the Chinese medicine preparation of above-mentioned treatment hepatopathy.
The preparation method of the Chinese medicine preparation of treatment hepatopathy disclosed by the invention comprises the following steps:
1, the preparation of Herba Clinopodii Polycephali total flavonoids extract
Get Herba Clinopodii Polycephali, alcoholic solution reflux, extract, with 20-95% 1-3 times, the medicinal liquid concentrating under reduced pressure, by absorption with macroporous adsorbent resin, colourless to effluent with water rinse resin, the alcoholic solution of reuse 20%-95% is washed resin, collect eluent, concentrate dry extract solid, Herba Clinopodii Polycephali total flavonoids content 〉=50% of getting.
Wherein used alcoholic solution is ethanol or methanol solution.
2, the preparation of injection
Get above-mentioned Herba Clinopodii Polycephali total flavonoids extract, add the dissolving of injection water, decolouring is filtered;
Aqueous injection is promptly made in filtrate such as direct embedding, sterilization; If lyophilizing is the lyophilizing pin after the sterilization fill; If directly sterilization, drying, pulverizing, fill are the powder pin; If promptly can be made into infusion solutions with the transfusion preparation; Made Herba Clinopodii Polycephali total flavonoids content is 3-10%.
3, the preparation of oral solid formulation
Take by weighing Herba Clinopodii Polycephali total flavonoids extract and pharmaceutic adjuvant by recipe quantity and granulate, make tablet, capsule, granule, powder etc. with conventional method with the bed spray granulation, make every, or bag the content of Herba Clinopodii Polycephali total flavonoids be 10mg-500mg.
Take by weighing Herba Clinopodii Polycephali total flavonoids extract and medicinal plant oil by recipe quantity, mixing is made soft capsule with the soft capsule unit, and the content that makes Herba Clinopodii Polycephali total flavonoids in every capsules is 10mg-500mg.
4, the preparation of cream
Take by weighing Herba Clinopodii Polycephali total flavonoids extract and pharmaceutic adjuvant by recipe quantity, make oil-in-water cream with conventional method, the content that makes the Herba Clinopodii Polycephali extractive of general flavone is 1%-10%.
5, the preparation of oral liquid
Take by weighing Herba Clinopodii Polycephali total flavonoids extract and pharmaceutic adjuvant by recipe quantity, make oral liquid with conventional method, the content that makes the Herba Clinopodii Polycephali extractive of general flavone is 1mg-50mg/ml.
A technical problem more to be solved by this invention provides the application of above-mentioned preparation in preparation treatment liver disease drug.
The Herba Clinopodii Polycephali total flavonoids extract that makes with the inventive method carries out relevant toxicity test, and the result is as follows:
1、LD
50＝5.3g/kg
2, the blood pressure of cat is breathed (conventional method) and do not see obvious influence
3, to the toxicity of Canis familiaris L.: total flavone injection 50ml adds 10% glucose injection 500ml intravenous drip.Blood pressure, hemobilirubin, blood potassium, blood SGPT and urobilinogen etc. are not all had obviously influence, and also not seeing has hemolytic reaction.
Experimental results show that: no overt toxicity, safety, effectively, can be for clinical.
The Herba Clinopodii Polycephali total flavonoids that makes with the inventive method carries out relevant pharmacology test, and the result is as follows:
1, Herba Clinopodii Polycephali total flavonoids is to the inhibition test of 2215 emiocytosis HBsAg and HBeAg
Table 1 Herba Clinopodii Polycephali total flavonoids is to the inhibition of 2215 emiocytosis HBsAg and HBeAg
Annotate: toxicity has appearred in "-" expression
2, Herba Clinopodii Polycephali total flavonoids causes the influence of chmice acute hepatic injury Serum ALT, AST to carbon tetrachloride
Table 2 Herba Clinopodii Polycephali total flavonoids causes the influence (X ± S) of chmice acute hepatic injury Serum ALT, AST to carbon tetrachloride
Annotate: * and blank group compare, P＜0.05; * and blank group compare, P＜0.01.
△Compare P＜0.05 with model control group;
△ △Compare P＜0.01 with model control group.
3, the pharmacological testing of the anti-dhbv dna of Herba Clinopodii Polycephali total flavonoids research
Each group treatment back meta suppression ratio situation of change of table 3
4, Herba Clinopodii Polycephali total flavonoids suppresses the pharmacological testing research of hepatoma carcinoma cell
Table 4 is respectively organized the rats death rate
The specific embodiment
The preparation of embodiment 1 Herba Clinopodii Polycephali total flavonoids extract
Get Herba Clinopodii Polycephali with 70% alcohol reflux three times, each 2h collects three times extracting solution, filters, and decompression recycling ethanol is not to there being the alcohol flavor, and thin up is to the 1ml/g crude drug, filtration.Filtrate is by the D101 macroporous adsorbent resin, and it is colourless to be washed to effluent, with 50% ethanol elution resin, collects eluent, reclaims ethanol, and drying gets extract solid, and Herba Clinopodii Polycephali total flavonoids content is 55%.
The preparation of embodiment 2 Herba Clinopodii Polycephali total flavonoids injection
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the dissolving of injection water, activated carbon decolorizing filters, and fill becomes 10ml/ to prop up behind the sterilization, makes every to contain Herba Clinopodii Polycephali total flavonoids 0.1g, injection for intravenous.
The preparation of embodiment 3 Herba Clinopodii Polycephali total flavonoids lyophilizing pins
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the dissolving of injection water, activated carbon decolorizing filters, fill behind the sterilization, and lyophilizing makes every to contain Herba Clinopodii Polycephali total flavonoids 0.3g.
The preparation of embodiment 4 Herba Clinopodii Polycephali total flavonoids tablets
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the maltodextrin of 5% weight, the microcrystalline Cellulose of 20% weight is used fluidized bed granulation, adds 1.5% magnesium stearate mixing back tabletting, and every contains Herba Clinopodii Polycephali total flavonoids 100mg.
The preparation of embodiment 5 Herba Clinopodii Polycephali total flavonoids hard capsules
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the maltodextrin of 15% weight, the microcrystalline Cellulose of 30% weight, 1% magnesium stearate incapsulates shell promptly after mixing, and every contains Herba Clinopodii Polycephali total flavonoids 150mg.
The preparation of embodiment 6 Herba Clinopodii Polycephali total flavonoids soft capsules
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the purified soyabean oil of 60% weight, be pressed into soft capsule promptly with the soft capsule unit behind the mixing, every contains Herba Clinopodii Polycephali total flavonoids 50mg.
The preparation of embodiment 7 Herba Clinopodii Polycephali total flavonoids granules
Get the Herba Clinopodii Polycephali total flavonoids extract that makes by embodiment 1 method, add the maltodextrin of 10% weight, the lactose of 40% weight is used fluidized bed granulation, divides and packs little generation into promptly, and every bag contains Herba Clinopodii Polycephali total flavonoids 300mg.
The preparation of embodiment 7 Herba Clinopodii Polycephali total flavonoids cream
Prescription:
Herba Clinopodii Polycephali total flavonoids 20g
Simethicone 50g
Liquid paraffin 150g
Stearic acid 120g
16 octadecanol 150g
Glycerol 200g
Water is an amount of
Make cream frost 1000g, Herba Clinopodii Polycephali total flavonoids content 1% with conventional method.
The preparation of embodiment 8 Herba Clinopodii Polycephali total flavonoids oral liquids
Herba Clinopodii Polycephali total flavonoids extract by embodiment 1 method makes with the purified water dissolving, adds 2% diphenolic acid sodium, sterilization, and sterilization back fill becomes 10ml/ to prop up, and makes every to contain Herba Clinopodii Polycephali total flavonoids 100mg.
The foregoing description only is to explanation of the present invention, and its protection domain is not limited in above embodiment.
Claims (1)
1. the application of Chinese medicine preparation in preparation treatment hepatitis B medicament that contains Herba Clinopodii Polycephali total flavonoids, it is characterized in that described Herba Clinopodii Polycephali total flavonoids Chinese medicine preparation is that 0.3-85% Herba Clinopodii Polycephali active component extract and 15-99.7% pharmaceutic adjuvant are formed by percentage by weight, main active Herba Clinopodii Polycephali total flavonoids content 〉=50% in the Herba Clinopodii Polycephali active component extract wherein, and make by following method: get Herba Clinopodii Polycephali, with the alcoholic solution reflux, extract, of 20-95% 1-3 time, the medicinal liquid concentrating under reduced pressure, pass through absorption with macroporous adsorbent resin, colourless with water rinse resin to effluent, the alcoholic solution of reuse 20%-95% is washed resin, collect eluent, concentrate, be drying to obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101111410A CN101322726B (en) | 2007-06-14 | 2007-06-14 | Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101111410A CN101322726B (en) | 2007-06-14 | 2007-06-14 | Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101322726A CN101322726A (en) | 2008-12-17 |
| CN101322726B true CN101322726B (en) | 2011-07-20 |
Family
ID=40186527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101111410A Expired - Fee Related CN101322726B (en) | 2007-06-14 | 2007-06-14 | Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101322726B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330724B (en) * | 2013-06-21 | 2016-05-04 | 陕西师范大学 | A kind of method of extracting scouring rush's general flavone |
| CN110101666A (en) * | 2019-05-22 | 2019-08-09 | 湖南华康生物科技股份有限公司 | The production method that a kind of low ash divides Horsetail P.E |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1957957A (en) * | 2006-11-17 | 2007-05-09 | 王成志 | Application of Bijian grass in preparing medication for treating disease of tinea of hands, and tinea pedis, and preparation method for product |
-
2007
- 2007-06-14 CN CN2007101111410A patent/CN101322726B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1957957A (en) * | 2006-11-17 | 2007-05-09 | 王成志 | Application of Bijian grass in preparing medication for treating disease of tinea of hands, and tinea pedis, and preparation method for product |
Non-Patent Citations (2)
| Title |
|---|
| 吴国土等.《笔管草醇提物的调节血脂作用》.《齐齐哈尔医学院学报》.2004,第25卷(第2期),121-123. * |
| 王小雄等.《节节草化学成分的研究》.《西北植物学报》.2005,第25卷(第12期),2524-2528. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101322726A (en) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103156869A (en) | Sanggenone C and sanggenone D extracted from morus plants and new medicine application of composition | |
| CN100479825C (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN102579554A (en) | Peanut stem and leaf extract and preparation method as well as application thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN101322726B (en) | Use of Chinese medicine preparation containing Hippochaete ramosissimum total flavones for preparing medicament for treating hepatitis | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN107375430A (en) | A kind of curcumin composition with preventing and treating diabetes and complication | |
| CN101513432A (en) | Preparation and new usage of selaginella tamariscina biflavone ingredient | |
| CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN100509009C (en) | A traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and ischemic stroke and its preparation method | |
| CN101167805B (en) | Use of medicinal composition containing lotus leaves and hypericum japonicum total flavone extraction in preparing medicine for hepatitis B virus | |
| CN102018740B (en) | Pharmaceutical composition containing sunflower leaf extract and use thereof | |
| CN100584357C (en) | Medicine composition containing borneol and musk | |
| CN100475218C (en) | Phyllostachys phylloxera extract and its preparation method and application | |
| CN101375954B (en) | Medicament composition, preparation method thereof and use | |
| CN101766702B (en) | Medicinal combination containing borneol and musk | |
| CN102552297B (en) | Application of medicinal composition in preparation of alpha-glucuroide inhibitor medicines | |
| CN100400037C (en) | Medicine composition containing borneol and musk | |
| CN1202839C (en) | Chinese medicine prepn for treating hepatosis and its prepn process | |
| CN101147757A (en) | Traditional Chinese medicine for treating chronic hepatitis B and its preparation process | |
| CN101766705B (en) | Medicinal combination containing borneol and musk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 650217 Yunnan city of Kunming province Kunming national economic and Technological Development Zone by Road No. 2 Patentee after: Kunming Huarun Saint fire Pharmaceutical Co., Ltd. Address before: 650217 Yunnan city of Kunming province Kunming national economic and Technological Development Zone by Road No. 2 Patentee before: Kunming Shenghuo Pharmaceutical (Group) Inc. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20210614 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |